{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:24:39Z","timestamp":1781108679296,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017527","name":"Jiangsu Cancer Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Ovarian carcinosarcomas (OCS) is a rare type of ovarian cancer. Due to its low incidence, studies are limited to several case reports\/case series and small-scale retrospective study. We carried out this study to explore prognostic factors and treatment strategies for OCS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with OCS between March 2012 and October 2023 at Jiangsu Cancer Center were enrolled in this study. Baseline Characteristics, treatment strategies and survival of all enrolled patients were recorded. Kaplan-Meier analysis with a log-rank Mantel-Cox test was used to compare progression-free survival (PFS) between different groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-six patients met inclusion criteria. The median PFS of all enrolled patients was 17.53 months. We firstly demonstrated that patients with ascites \u2265500 ml (27.83 months <jats:italic>vs.<\/jats:italic> 13.7 months, <jats:italic>p<\/jats:italic>=0.12, HR 0.72), age \u226558 years (22.93 months <jats:italic>vs.<\/jats:italic> 13.53 months, <jats:italic>p<\/jats:italic>=0.354, HR 0.62), diameter of tumor&amp;lt;10cm (27.83 months vs. 12.80 months, <jats:italic>p<\/jats:italic>=0.095, HR 0.36), Ki-67 \u226570% (22.93 months <jats:italic>vs.<\/jats:italic> 13.53 months, <jats:italic>p<\/jats:italic>=0.093, HR 0.39) had a trend of better prognosis. Five patients underwent genetic testing, 4 of whom were homologous recombination deficiency (HRD)-positive and treated with PARP inhibitor (PARPi). The median PFS of the 4 patients was 22.68 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study demonstrated that age at diagnosis, diameter of tumor, Ki-67 index, and volume of ascites may be prognostic factors of OCS. Patients with HRD positive\/BReast CAncer gene (BRCA) mutation may benefit from PARPi.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1577139","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:10:52Z","timestamp":1749528652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China"],"prefix":"10.3389","volume":"15","author":[{"given":"Wanwan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000228","article-title":"Harter P et\u00a0al: Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma","volume":"24","author":"Berton-Rigaud","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-019-0507-3","article-title":"A rare case of ovarian carcinosarcoma with squamous cell carcinoma","volume":"12","author":"Daimon","year":"2019","journal-title":"J Ovarian Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3802\/jgo.2024.35.e31","article-title":"Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea","volume":"35","author":"Ha","year":"2024","journal-title":"J Gynecologic Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.02.016","article-title":"Survival of women diagnosed with Malignant, mixed mullerian tumors of the ovary (OMMMT)","volume":"93","author":"Barnholtz-Sloan","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01874-8","article-title":"Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma","volume":"127","author":"Hollis","year":"2022","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000092134.88121.56","article-title":"Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis","volume":"22","author":"Jin","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v100:10","article-title":"Carcinosarcoma of the ovary: 19 years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.0000\/PMID23482773","article-title":"A population-based series of ovarian carcinosarcomas with long-term follow-up","volume":"33","author":"Paulsson","year":"2013","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","article-title":"Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis","volume":"131","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00919.x","article-title":"The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy","volume":"17","author":"Athavale","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00757.x","article-title":"Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas","volume":"116","author":"N\u00e4yh\u00e4","year":"2008","journal-title":"APMIS"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/107155769400100302","article-title":"Pathogenesis of ovarian cancers","volume":"1","author":"Berchuck","year":"1994","journal-title":"J Soc Gynecol Investig"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950715)76:2<291::AID-CNCR2820760220>3.0.CO;2-2","article-title":"Overexpression or mutation of the p53 tumor suppressor gene does not occur in Malignant ovarian germ cell tumors","volume":"76","author":"Liu","year":"1995","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0015","article-title":"The expression of epidermal growth factor receptor, HER-2\/Neu, p53, and Ki-67 antigen in uterine Malignant mixed mesodermal tumors and adenosarcoma","volume":"60","author":"Swisher","year":"1996","journal-title":"Gynecol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.02.023","article-title":"Carcinosarcoma of the ovary: a case-control study","volume":"121","author":"Rauh-Hain","year":"2011","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059312","article-title":"Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients","volume":"6","author":"Chang","year":"1995","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600770","article-title":"Reynolds K et\u00a0al: Carcinosarcoma of the ovary","volume":"88","author":"Harris","year":"2003","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4","article-title":"Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction","volume":"82","author":"Sood","year":"1998","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"Mooney M et\u00a0al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/PAS.0b013e318198177d","article-title":"SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma","volume":"33","author":"Cao","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"153028","DOI":"10.1016\/j.prp.2020.153028","article-title":"An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases","volume":"216","author":"Karpathiou","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"569609","DOI":"10.1155\/2012\/569609","article-title":"Malignant mixed mullerian tumor: an immunohistochemical study","volume":"2012","author":"Bing","year":"2012","journal-title":"Patholog Res Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880813","article-title":"Expression of CD10 in Malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study","volume":"15","author":"Zamecnik M: Correspondence re: Mikami","year":"2002","journal-title":"Mod Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.2017.60.4.350","article-title":"Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma","volume":"60","author":"Kim","year":"2017","journal-title":"Obstet Gynecol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(85)90061-1","article-title":"Malignant mixed mesodermal tumor of the ovary: a report of 22 cases","volume":"65","year":"1985","journal-title":"Obstet Gynecol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197101)27:1<207::AID-CNCR2820270129>3.0.CO;2-0","article-title":"Carcinosarcomas and mixed mesodermal tumors of the ovary","volume":"27","author":"Dehner","year":"1971","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0191-x","article-title":"Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer","volume":"119","author":"Carter","year":"2018","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics9040200","article-title":"Truskinovsky A et\u00a0al: Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience","volume":"9","author":"Nizam","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12885-018-4082-6","article-title":"Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature","volume":"18","author":"Brackmann","year":"2018","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms252011239","article-title":"Saponara S et\u00a0al: The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer","volume":"25","author":"Tonti","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.603591","article-title":"Case report: niraparib as maintenance therapy in A patient with ovarian carcinosarcoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2023.09.045","article-title":"Treatment of HRD-positive ovarian carcinosarcoma: A case report and literature review","volume":"46","author":"Lin","year":"2023","journal-title":"Asian J Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1577139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:10:53Z","timestamp":1749528653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1577139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1577139"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1577139","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"article-number":"1577139"}}